Madrigal Pharmaceuticals, Inc.
Símbolo: MDGL
NASDAQ
229.84
USDPrecio de mercado actual
-12.1269
Ratio PER
-0.3892
Ratio PEG
4.83B
Capitalización MRK
- 0.00%
Rendimiento DIV
Madrigal Pharmaceuticals, Inc. (MDGL) Estados Financieros
Balance de situación
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2001 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1494.38 | 634.1 | 358.8 | 270.3 | ||||||||||||||||||||||
balance-sheet.row.short-term-investments | 1141.9 | 534.2 | 27.2 | 234.1 | ||||||||||||||||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.other-current-assets | 11.25 | 3.1 | 2.6 | 1.3 | ||||||||||||||||||||||
balance-sheet.row.total-current-assets | 1505.63 | 637.3 | 361.4 | 271.7 | ||||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 7.79 | 3.3 | 1.2 | 1.6 | ||||||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 7.79 | 3.3 | 1.2 | 1.6 | ||||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.total-assets | 1513.42 | 640.5 | 362.6 | 273.3 | ||||||||||||||||||||||
balance-sheet.row.account-payables | 74.25 | 28 | 23.8 | 21.4 | ||||||||||||||||||||||
balance-sheet.row.short-term-debt | 2.1 | 0.5 | 0.6 | 0.4 | ||||||||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 414.74 | 115.5 | 49.3 | 0.4 | ||||||||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||||||||
balance-sheet.row.other-current-liab | 339.92 | 90 | 91.5 | 55 | ||||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 415.93 | 116.7 | 49.3 | 0.4 | ||||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 4.09 | 1.2 | 0.6 | 0.8 | ||||||||||||||||||||||
balance-sheet.row.total-liab | 832.2 | 235.2 | 165.2 | 77.2 | ||||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.common-stock | 0.01 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.retained-earnings | -4725.3 | -1336.3 | -962.7 | -667.3 | ||||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0.25 | 0.5 | 0 | -0.1 | ||||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 5406.26 | 1741.2 | 1160.1 | 863.5 | ||||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 681.22 | 405.3 | 197.4 | 196.1 | ||||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 1513.42 | 640.5 | 362.6 | 273.3 | ||||||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
balance-sheet.row.total-equity | 681.22 | 405.3 | 197.4 | 196.1 | ||||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 1513.42 | - | - | - | ||||||||||||||||||||||
Total Investments | 1141.9 | 534.2 | 27.2 | 234.1 | ||||||||||||||||||||||
balance-sheet.row.total-debt | 418.03 | 117.2 | 49.9 | 0.8 | ||||||||||||||||||||||
balance-sheet.row.net-debt | 65.56 | 17.3 | -281.7 | -35.5 |
Estado de tesorería
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -373.63 | -373.6 | -295.4 | -241.8 | |||||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0.53 | 0.5 | 0.5 | 0.4 | |||||||||||||||||||||
cash-flows.row.deferred-income-tax | -3.64 | -4.2 | 0 | -7.3 | |||||||||||||||||||||
cash-flows.row.stock-based-compensation | 49.73 | 49.7 | 31.6 | 26.9 | |||||||||||||||||||||
cash-flows.row.change-in-working-capital | -3.28 | -3.3 | 37.6 | 30.7 | |||||||||||||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | |||||||||||||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | |||||||||||||||||||||
cash-flows.row.account-payables | 4.21 | 4.2 | 2.5 | 20.4 | |||||||||||||||||||||
cash-flows.row.other-working-capital | 11.49 | -7.5 | 35.2 | 10.3 | |||||||||||||||||||||
cash-flows.row.other-non-cash-items | 6.05 | 6.6 | 0.8 | 7.3 | |||||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -324.23 | 0 | 0 | 0 | |||||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -1.48 | -1.5 | -0.2 | -0.2 | |||||||||||||||||||||
cash-flows.row.acquisitions-net | -1.85 | -5.5 | 0 | 0.8 | |||||||||||||||||||||
cash-flows.row.purchases-of-investments | -834.44 | -834.4 | -143.5 | -394.1 | |||||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 333.4 | 333.4 | 350.4 | 389.3 | |||||||||||||||||||||
cash-flows.row.other-investing-activites | 1.85 | 5.5 | 0 | -0.8 | |||||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -502.52 | -502.5 | 206.7 | -5.1 | |||||||||||||||||||||
cash-flows.row.debt-repayment | -64.64 | -64.6 | -49.1 | 0 | |||||||||||||||||||||
cash-flows.row.common-stock-issued | 504.4 | 530.5 | 255.4 | 170.2 | |||||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||||||||||
cash-flows.row.other-financing-activites | 155.83 | 129.3 | 107.2 | 1 | |||||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 595.12 | 595.1 | 313.5 | 171.2 | |||||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 58.06 | 0 | 0 | 0 | |||||||||||||||||||||
cash-flows.row.net-change-in-cash | -231.63 | -231.6 | 295.3 | -17.7 | |||||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 352.47 | 99.9 | 331.5 | 36.3 | |||||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 584.11 | 331.5 | 36.3 | 54 | |||||||||||||||||||||
cash-flows.row.operating-cash-flow | -324.23 | -324.2 | -224.9 | -183.9 | |||||||||||||||||||||
cash-flows.row.capital-expenditure | -1.48 | -1.5 | -0.2 | -0.2 | |||||||||||||||||||||
cash-flows.row.free-cash-flow | -325.71 | -325.7 | -225.1 | -184.1 |
Fila de la Cuenta de Resultados
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 0.53 | 0.5 | 0.5 | 0.4 | |||||||||||||||||||||||
income-statement-row.row.gross-profit | -0.53 | -0.5 | -0.5 | -0.4 | |||||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
income-statement-row.row.research-development | 272.21 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 108.15 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0.3 | |||||||||||||||||||||||
income-statement-row.row.operating-expenses | 380.35 | 380 | 293.6 | 242.5 | |||||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 380.5 | 380.5 | 293.6 | 242.5 | |||||||||||||||||||||||
income-statement-row.row.interest-income | 19.58 | 19.6 | 2.2 | 0.4 | |||||||||||||||||||||||
income-statement-row.row.interest-expense | 5.7 | 12.7 | 4 | 0 | |||||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 6.87 | 6.9 | -1.8 | 0.6 | |||||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0.3 | |||||||||||||||||||||||
income-statement-row.row.total-operating-expenses | 6.87 | 6.9 | -1.8 | 0.6 | |||||||||||||||||||||||
income-statement-row.row.interest-expense | 5.7 | 12.7 | 4 | 0 | |||||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 4.3 | 0.5 | 2.2 | 0.4 | |||||||||||||||||||||||
income-statement-row.row.ebitda-caps | -372.9 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.operating-income | -380.5 | -380.5 | -293.6 | -242.5 | |||||||||||||||||||||||
income-statement-row.row.income-before-tax | -373.63 | -373.6 | -295.4 | -241.8 | |||||||||||||||||||||||
income-statement-row.row.income-tax-expense | 4.19 | 0 | 4 | -0.8 | |||||||||||||||||||||||
income-statement-row.row.net-income | -374.53 | -373.6 | -299.3 | -241.1 |
Preguntas frecuentes
Cuánto es Madrigal Pharmaceuticals, Inc. (MDGL) activos totales?
Madrigal Pharmaceuticals, Inc. (MDGL) los activos totales son 640547000.000.
¿Cuáles son los ingresos anuales de la empresa?
Los ingresos anuales son N/A.
¿Cuál es el margen de beneficios de la empresa?
El margen de beneficios de la empresa es 0.000.
¿Qué es el flujo de caja libre de la empresa?
El flujo de caja libre es -16.483.
¿Cuál es el margen de beneficio neto de la empresa?
El margen de beneficio neto es 0.000.
¿Cuáles son los ingresos totales de la empresa?
Los ingresos totales son 0.000.
¿Qué es Madrigal Pharmaceuticals, Inc. (MDGL) beneficio neto (ingresos netos)?
El beneficio neto (ingresos netos) es -373630000.000.
¿Cuál es la deuda total de la empresa?
La deuda total es 117193000.000.
¿Cuál es la cifra de gastos de explotación?
Los gastos de explotación son 379969000.000.
¿Cuál es la cifra de tesorería de la empresa?
La tesorería de la empresa es 99915000.000.